{"id":44306,"date":"2025-10-24T23:14:48","date_gmt":"2025-10-24T15:14:48","guid":{"rendered":"https:\/\/flcube.com\/?p=44306"},"modified":"2025-10-24T23:14:48","modified_gmt":"2025-10-24T15:14:48","slug":"astellas-china-secures-gba-approval-for-first%e2%80%91in%e2%80%91class-fezolinetant-veoza","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44306","title":{"rendered":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)"},"content":{"rendered":"\n<p>Astellas (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist <strong>VEOZA (Fezolinetant)<\/strong> has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-why-veoza-matters\"><strong>Why VEOZA Matters<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011of\u2011its\u2011kind<\/strong>: The world\u2019s first approved non\u2011hormonal NK3 antagonist for moderate\u2011to\u2011severe vasomotor symptoms (VMS) of menopause.<\/li>\n\n\n\n<li><strong>Targeted therapy<\/strong>: Selectively blocks NK3 receptors\u2014key drivers of hot flashes and night sweats.<\/li>\n\n\n\n<li><strong>Improved quality of life<\/strong>: Reduces sleep disturbance, fatigue, cognitive \u201cbrain fog,\u201d and mood irritability in menopausal women.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-details\"><strong>Key Details<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Information<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>VEOZA (Fezolinetant)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate\u2011to\u2011severe vasomotor symptoms (hot flashes\/night sweats) in post\u2011menopausal women<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>GBA launch via HK\u2011Macao Connect policy<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Approved under the Hong\u202fKong\u2011Macao Medicine and Equipment Connect framework<\/td><\/tr><tr><td><strong>Market Impact<\/strong><\/td><td>Addresses a high\u2011volume unmet need; expected to capture significant share of the GBA menopause\u2011symptom market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-gba-market-opportunity\"><strong>GBA Market Opportunity<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong>: Over 70\u202fmillion residents in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area.<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: ~40\u202f% of menopausal women report moderate\u2011to\u2011severe VMS; current hormonal therapies pose safety concerns.<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Non\u2011hormonal profile reduces risk of breast cancer and cardiovascular events, differentiating VEOZA from existing options.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-astellas-strategic-vision\"><strong>Astellas\u2019 Strategic Vision<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage<\/strong>: By leveraging HK\u2011Macao Connect, Astellas positions VEOZA as the first NK3 antagonist available in the GBA, capturing early market share.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong>: Success in the GBA will inform rollout plans in other Asian markets and beyond.<\/li>\n\n\n\n<li><strong>Patient\u2011Centric Approach<\/strong>: Ongoing patient support programs and real\u2011world evidence collection to demonstrate long\u2011term benefit.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h2>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44308,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[353,15,1177],"class_list":["post-44306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astellas-pharma","tag-product-approvals","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA) - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist VEOZA (Fezolinetant) has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44306\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)\" \/>\n<meta property=\"og:description\" content=\"Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist VEOZA (Fezolinetant) has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44306\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-24T15:14:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)\",\"datePublished\":\"2025-10-24T15:14:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306\"},\"wordCount\":309,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2406.webp\",\"keywords\":[\"Astellas Pharma\",\"Product approvals\",\"TYO: 4503\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44306#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44306\",\"name\":\"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA) - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2406.webp\",\"datePublished\":\"2025-10-24T15:14:48+00:00\",\"description\":\"Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist VEOZA (Fezolinetant) has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44306\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2406.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2406.webp\",\"width\":1080,\"height\":608,\"caption\":\"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44306#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA) - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist VEOZA (Fezolinetant) has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44306","og_locale":"en_US","og_type":"article","og_title":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)","og_description":"Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist VEOZA (Fezolinetant) has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.","og_url":"https:\/\/flcube.com\/?p=44306","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-24T15:14:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44306#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44306"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)","datePublished":"2025-10-24T15:14:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44306"},"wordCount":309,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44306#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp","keywords":["Astellas Pharma","Product approvals","TYO: 4503"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44306#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44306","url":"https:\/\/flcube.com\/?p=44306","name":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA) - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44306#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44306#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp","datePublished":"2025-10-24T15:14:48+00:00","description":"Astellas (TYO: 4503) China announced that its global first\u2011in\u2011class, non\u2011hormonal, selective neurokinin\u20113 (NK3) receptor antagonist VEOZA (Fezolinetant) has received official approval for launch in the Guangdong\u2011Hong\u202fKong\u2011Macao Greater Bay Area (GBA) under the \u201cHong\u202fKong\u2011Macao Medicine and Equipment Connect\u201d (HK\u2011Macao Connect) policy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44306#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44306"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44306#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp","width":1080,"height":608,"caption":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44306#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas China Secures GBA Approval for First\u2011in\u2011Class Fezolinetant (VEOZA)"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2406.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44306"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44306\/revisions"}],"predecessor-version":[{"id":44309,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44306\/revisions\/44309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44308"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}